An Open-Label, Brain Imaging Study Using Positron Emission Tomography with 18F-FDG and MRI with Arterial Spin Labeling to Determine Changes in Brain Glucose Metabolism and Cerebral Blood Flow after Single-Dose Intravenous Administration of CST-101 in Healthy Subjects and Patients with Mild Cognitive Impairment
Latest Information Update: 02 Jul 2019
At a glance
- Drugs CST 101 (Primary) ; CST 101 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment; Neurodegenerative disorders; Parkinson's disease
- Focus Therapeutic Use
- Sponsors CuraSen Therapeutics
- 27 Mar 2019 New trial record
- 21 Mar 2019 According to Australian New Zealand Clinical Trials Registry,the anticipated date for last participant enrollment is 6/28/2019.